NAD+ Precursor Chews vs. Fish Oil for Senior Dog Vitality: Reading the Evidence Before the Claim

By Koranda Walsh, VMD, DACVIM (SAIM), DACVP (CP)

Comparisons · August 14, 2026 · 7 min read

Fish oil has decades of dosed, published evidence behind it; NAD+ precursor chews have one good trial and a lot of marketing riding ahead of it.

Before you buy either one, check these four things:

• Does the label list an actual analyte and dose — milligrams of EPA+DHA per chew, or milligrams of nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN) — or just a proprietary blend weight?
• Is there a NASC Quality Seal or equivalent third-party testing on the product, not just a claim of it?
• Is the vitality claim backed by a dosed trial in dogs, or borrowed from human or rodent NAD+ literature?
• What is the owner actually trying to fix — stiffness and inflammation (fish oil’s home turf) or flagging alertness and stamina (where NAD+ precursors are being marketed, with thinner data)?

I’ll take those in order, because the order matters more than either ingredient does on its own.

A twelve-year-old spayed female mixed-breed, forty-one pounds, came in for her senior wellness exam on a Tuesday morning in February, and her owner had a question I now get almost weekly: should she add an NAD+ chew on top of the fish oil the dog had been on for six years? The dog wasn’t limping. She was slower on stairs, slept later, and had stopped meeting the owner at the door with the same enthusiasm — the kind of change that shows up over months, not days, and that owners often can’t date precisely. That vagueness is the whole problem with “vitality” as an outcome. It isn’t a lab value. It’s an owner’s impression, and impressions are exactly what a hopeful new supplement category is best at moving, whether or not the underlying biology has actually changed.

What fish oil is actually measured against

Omega-3 fatty acids — specifically EPA and DHA — are the most studied supplement class in veterinary medicine, and that matters here because “studied” is not the same as “hyped.” Their mechanism is boring in the best way: EPA and DHA get incorporated into cell membranes and shift the balance of inflammatory mediators produced from those membranes, which is why the strongest, most reproducible evidence sits in joint comfort and skin/coat condition rather than in energy per se. On cognition, DHA’s role is more structural than acute — it’s a major component of neural membranes, and diets enriched with it have been associated with cognitive benefits in aging dogs, a pattern also described in a 2024 review on n-3 PUFA and PMC: cognitive function. That’s a real signal, but read it for what it is: membrane composition and inflammatory tone, not a jolt of energy.

The label is where fish oil separates from the marketing noise. A product that states milligrams of EPA and DHA per serving, and carries a National Animal Supplement Council: NASC Quality Seal, has been through a documented sourcing and testing audit — heavy metals, oxidation, and potency are the kinds of things that seal is meant to catch, since fish oil rancidity is a real and underappreciated failure mode. A product that just says “fish oil” with a proprietary blend weight hasn’t told you anything a bloodwork panel would respect.

Where NAD+ precursor chews actually stand

NAD+ is a coenzyme central to cellular energy metabolism, and it does decline with age — that part isn’t controversial. The pitch for precursor chews (usually built around NR or NMN) is that restoring NAD+ levels restores some of the cellular machinery that ages out. In humans, nicotinamide riboside has been shown to be orally bioavailable and to reliably raise blood NAD+ levels in a well-tolerated way, per a trial published in Nature Communications. That’s a pharmacokinetic finding, not a vitality claim — it tells you the compound gets absorbed and does what it’s supposed to do at the molecular level, nothing about whether the dog feels or acts different.

The dog-specific evidence is thinner but not nonexistent. A randomized controlled trial published in Scientific Reports found improved owner-assessed cognitive function in senior dogs given a combination senolytic and NAD+ precursor product, with a measurable difference from baseline at the primary endpoint compared to placebo — a genuinely notable result, reported in A Randomized, Controlled Clinical Trial Demonstrates Improved Owner-Assessed Cognitive Function in Senior Dogs. Read the fine print, though: it’s owner-assessed, it’s one trial, and it tested a combination product (senolytic plus NAD+ precursor), not an NAD+ precursor chew in isolation. That’s an important distinction if you’re trying to attribute the effect to NAD+ alone. This is a reasonable trial to point to. It is not yet the kind of accumulated, repeated evidence base that omega-3s have behind them.

In my practice, I tell owners the honest version of that gap directly: one good trial earns cautious interest, not a verdict. I’ve watched a fourteen-year-old beagle mix go on an NAD+ precursor chew after his owner read about the Scientific Reports trial online, hoping to see the alertness her dog had five years earlier come back within a month. What she actually saw, by her own report at the eight-week recheck, was subtler — he still slept most of the afternoon, but he was pacing at the door for his evening walk again, something he’d stopped doing that winter. I can’t tell you that was the NAD+ precursor and not the milder spring weather, and I said so. That’s the honest limit of a case: it’s one dog, one report, and it doesn’t replace a dosed trial.

Reading the bloodwork, not the bottle

This is where the label-versus-lab-value distinction actually earns its keep. Neither fish oil nor an NAD+ precursor chew shows up as a discrete analyte on a standard senior wellness panel — you won’t see “NAD+ level: normal” on a CBC/chemistry printout. What you can and should track instead are the values a vitality complaint might actually be masking: a low free T4 on thyroid screening, a mild anemia dragging down a hematocrit, an elevated ALP or bile acids pattern suggesting liver strain, or early azotemia on kidney values. Owners come in ready to add a supplement to fix flagging energy; the more useful first move is often a chemistry panel and CBC to rule out the things a chew can’t touch. A supplement — of either kind — is not a substitute for that workup, and no responsible product claims otherwise on its label, which is itself a tell about which labels to trust.

For dogs already diagnosed with an inflammatory joint condition, arthritis, or a skin/coat issue, the omega-3 evidence is dosed and disease-specific enough to guide a real recommendation — see our companion piece on postbiotics vs. fish oil for dog inflammation for how that comparison plays out against another category. If stiffness is the real complaint rather than general vitality, it’s also worth ruling out ordinary aging change first; we cover that distinction in arthritis vs. normal aging stiffness in dogs.

Form matters for both categories, and it’s a separate question from ingredient choice. A chew that isn’t dosed and split correctly for a small dog’s weight, or that degrades because of how it was manufactured, won’t deliver what the label promises regardless of which molecule is inside it — we go through that in chew vs. powder vs. liquid supplements for dogs and, for multi-supplement senior dogs specifically, splitting multiple different chews for a small dog.

The verdict

Here’s where I land, and where I expect some pushback from owners already sold on the newer category: fish oil earns a confident recommendation for a senior dog with joint stiffness, coat dullness, or documented inflammatory issues, provided the label states actual EPA/DHA milligrams and carries independent testing. NAD+ precursor chews earn cautious, conditional interest — the Scientific Reports trial is real and worth taking seriously, but it tested a combination product, it’s owner-reported, and it hasn’t been repeated. The strongest counterargument I hear is that senior dogs don’t have time to wait for the evidence to mature, and that’s fair; aging doesn’t pause for a second RCT. But “we don’t have time to wait” is an argument for trying a product cautiously and tracking real markers, not for treating one trial as settled science. I’d rather an owner add an NAD+ precursor chew on top of a well-dosed omega-3, with bloodwork ruling out other causes first, than swap one for the other on the strength of a single study.

One more scene, because it’s the one that changed how I frame this conversation: an eleven-year-old Cavalier King Charles Spaniel, twenty-two pounds, came in because his owner said he’d “stopped being a puppy” almost overnight, sometime around Thanksgiving. Bloodwork showed a mildly elevated ALT and a fasting bile acids result that pointed toward early hepatic strain — not dramatic, but real, and not something either fish oil or an NAD+ chew would have touched. We treated the liver finding, rechecked him ten weeks later, and his owner reported he was back to greeting her at the door. The lesson I keep coming back to, and the one I’d want every owner reading this to take: run the bloodwork before you reach for either bottle. The label can tell you what’s in the product. Only the lab value can tell you whether the product was ever the right answer for this dog.